HC Wainwright Issues Optimistic Forecast for AVBP Earnings

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Research analysts at HC Wainwright raised their Q3 2025 EPS estimates for ArriVent BioPharma in a note issued to investors on Tuesday, August 12th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.82) per share for the quarter, up from their prior forecast of ($0.83). HC Wainwright currently has a “Buy” rating and a $42.00 target price on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($2.74) per share. HC Wainwright also issued estimates for ArriVent BioPharma’s Q4 2025 earnings at ($0.80) EPS, FY2025 earnings at ($4.30) EPS, Q1 2026 earnings at ($0.83) EPS, Q2 2026 earnings at ($0.85) EPS, Q3 2026 earnings at ($0.88) EPS, Q4 2026 earnings at ($0.91) EPS and FY2026 earnings at ($3.47) EPS.

ArriVent BioPharma (NASDAQ:AVBP) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.20).

A number of other equities analysts have also weighed in on AVBP. Wall Street Zen lowered shares of ArriVent BioPharma from a “hold” rating to a “strong sell” rating in a research report on Thursday, May 22nd. Citigroup reissued a “buy” rating and issued a $33.00 price objective (down previously from $40.00) on shares of ArriVent BioPharma in a research report on Tuesday. Jones Trading initiated coverage on shares of ArriVent BioPharma in a research report on Tuesday, May 20th. They set a “buy” rating and a $40.00 price target for the company. Oppenheimer reaffirmed an “outperform” rating and set a $44.00 price target (up previously from $39.00) on shares of ArriVent BioPharma in a research report on Tuesday, June 24th. Finally, Guggenheim reaffirmed a “buy” rating and set a $45.00 price target on shares of ArriVent BioPharma in a research report on Tuesday, June 24th. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $39.14.

ArriVent BioPharma Price Performance

NASDAQ:AVBP opened at $19.53 on Friday. The firm has a 50 day simple moving average of $21.40 and a 200-day simple moving average of $21.53. The firm has a market cap of $792.33 million, a PE ratio of -4.86 and a beta of 1.17. ArriVent BioPharma has a 1-year low of $15.47 and a 1-year high of $36.37.

Hedge Funds Weigh In On ArriVent BioPharma

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Suvretta Capital Management LLC grew its stake in ArriVent BioPharma by 21.7% during the fourth quarter. Suvretta Capital Management LLC now owns 2,246,000 shares of the company’s stock worth $59,833,000 after buying an additional 400,838 shares during the period. Infinitum Asset Management LLC grew its stake in ArriVent BioPharma by 25.7% during the first quarter. Infinitum Asset Management LLC now owns 2,066,238 shares of the company’s stock worth $38,205,000 after buying an additional 422,315 shares during the period. Octagon Capital Advisors LP grew its stake in ArriVent BioPharma by 4.2% during the fourth quarter. Octagon Capital Advisors LP now owns 2,059,387 shares of the company’s stock worth $54,862,000 after buying an additional 83,000 shares during the period. Novo Holdings A S grew its stake in ArriVent BioPharma by 1.0% during the fourth quarter. Novo Holdings A S now owns 1,520,627 shares of the company’s stock worth $40,510,000 after buying an additional 15,312 shares during the period. Finally, Vanguard Group Inc. grew its stake in ArriVent BioPharma by 6.1% during the first quarter. Vanguard Group Inc. now owns 1,503,358 shares of the company’s stock worth $27,797,000 after buying an additional 86,067 shares during the period. Institutional investors and hedge funds own 9.48% of the company’s stock.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.